Latest Breast cancer treatment Stories
REDWOOD CITY, Calif., June 1, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 18 studies being presented at the American Society for Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place June 1-5 in Chicago, Illinois. New data includes validation of the Oncotype DX® colon cancer test in both stage II and stage III disease, the company's first prostate needle biopsy development study, and further evidence of the clinical value of the...
IRVINE, Calif. and AMSTERDAM, June 1, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery. ColoPrint provides a definitive relapse risk assessment for 100 percent of all stage II patients and eliminates the gray area of...
SEATTLE, May 31, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib (Zelboraf®). PX-866 is Oncothyreon's investigational small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. Vemurafenib is a kinase inhibitor indicated for the treatment of unresectable or metastatic melanoma...
CLEVELAND, May 30, 2012 /PRNewswire/ -- ViewRay(TM) Incorporated, a privately held medical device company, has received U.S. FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system. The ViewRay system features a unique combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance in 2011. "FDA...
Women receiving care for breast cancer have significantly impaired cardio-pulmonary function that can persist for years after they have completed treatment, according to a study led by scientists at Duke University Medical Center. The findings, reported online in the Journal of Clinical Oncology, also provide initial evidence that poor cardio-pulmonary function may be a strong predictor of survival among women with advanced breast cancer. "We know that exercise tolerance tests, which...
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology. Women with breast cancer often undergo chemotherapy prior to surgery. Research has shown that women who receive this treatment, known as neoadjuvant chemotherapy, are more likely to achieve breast conservation than those receiving chemotherapy...
SOUTH SAN FRANCISCO, Calif., May 23, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (mCRC). Regorafenib is a Bayer compound, and Onyx will receive a royalty on global net sales of regorafenib in oncology. The submission is...
(Ivanhoe Newswire) – A new study shows that magnetic resonance imaging (MRI), when compared with clinical examination, can actually give an earlier indication of a breast tumor’s response to pre-surgical chemotherapy. Research shows that women who receive chemotherapy before surgery, known as neoadjuvant chemotherapy, are more likely to achieve breast conservation compared with those receiving chemotherapy after surgery. Traditionally, clinicians monitor the patient’s response to...
WORCESTER, Mass. and TORONTO, May 18, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that additional members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company's AE37 breast cancer vaccine. The following distinguished scientists, scholars, and physicians join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD...
LUNGevity, Nation's Largest Lung Cancer-focused Nonprofit, Funds Critical, Encouraging Research WASHINGTON, May 17, 2012 /PRNewswire-USNewswire/ -- LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to note promising updates in researchers' quest for early detection and treatments for lung cancer during May, Lung Cancer Hope Month. Renowned researchers and LUNGevity Science Board Members, including Dr. Pierre Massion, Vanderbilt University Medical...
